注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Oasmia Pharmaceutical AB是一家总部位于瑞典的制药公司,致力于通过增强诸如癌症等疾病的药物的静脉内输送来改善患者的生活。产品开发基于Oasmia的药物输送平台,该平台可应用于许多治疗领域中的药物,以开发通常需要化学增溶剂溶解的药物的水溶性制剂。使用该技术的公司认可产品为Apealea(紫杉醇胶束)。Apealea在欧盟和其他多个地区获得市场许可,可与卡铂联合治疗铂敏感型卵巢癌的首次复发。该公司通过与Elevar Therapeutics的合作以及在北欧地区的现有商业运营,使Apealea可以为患者使用。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Göran Pettersson | 77 | 2019 | Chairman of Business Advisory Board |
Rolf Lewensohn | - | 2019 | Chairman of Scientific Advisory Board |
Roger Tell | - | 2022 | Director |
Pal Ryfors | - | 2022 | Director |
Peter Zonabend | 43 | 2019 | Chairman of the Board |
Ola S. Winqvist | 61 | 2019 | Member of Scientific Advisory Board |
Hans Grönlund | - | 2019 | Member of Scientific Advisory Board |
Kerstin Valinder Strinnholm | 63 | 2019 | Member of Business Advisory Board |
Mohammed Homman | 49 | 2019 | Member of Business Advisory Board |
Jacob Kaluski | 73 | 2019 | Member of Business Advisory Board |
Hege Hellstrom | 58 | 2019 | Member of Business Advisory Board & Independent Director |
Pal Ryfors | 40 | 2022 | Independent Director |
Roger Tell | 58 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核